ReviewZeitschrift fur Rheumatologie2026
[New biomarker-based diagnostic tests : Early and precise diagnosis of rheumatological diseases].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers play a central role in rheumatology for early detection, prognostic assessment, treatment stratification, and evaluation of the disease course, as early and targeted therapies are crucial for prognosis. In rheumatoid arthritis, rheumatoid factors and anti-citrullinated protein (CCP) antibodies are established diagnostic and prognostic biomarkers. For seronegative spondyloarthritis, HLA-B27 is the most important diagnostic marker, particularly in axial spondyloarthritis. In connective tissue diseases, antinuclear antibodies are essential for diagnosis, but their use for assessing activity is limited. Specific autoantibodies, complement factors, and urinary biomarkers are prognostically particularly relevant in systemic lupus erythematosus. In vasculitis diagnostics, anti-neutrophil cytoplasmic antibodies (ANCAs; anti-myeloperoxidase and anti-proteinase 3) are essential for small-vessel vasculitis, while serological markers for large-vessel vasculitis are lacking.
Indexed as
Identifiers
42149252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.